Imagion Biosystems Ltd (IBX) - Net Assets
Based on the latest financial reports, Imagion Biosystems Ltd (IBX) has net assets worth AU$-2.16 Million AUD (≈ $-1.53 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.04 Million ≈ $1.45 Million USD) and total liabilities (AU$4.21 Million ≈ $2.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IBX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-2.16 Million |
| % of Total Assets | -105.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -116.25% |
| 10-Year Change | -118.49% |
| Growth Volatility | 147.76 |
Imagion Biosystems Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Imagion Biosystems Ltd's net assets have evolved over time, based on quarterly financial data. See Imagion Biosystems Ltd (IBX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Imagion Biosystems Ltd (2014–2025)
The table below shows the annual net assets of Imagion Biosystems Ltd from 2014 to 2025. For live valuation and market cap data, see market cap of Imagion Biosystems Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$-2.16 Million ≈ $-1.53 Million |
+5.30% |
| 2024-12-31 | AU$-2.28 Million ≈ $-1.62 Million |
+39.73% |
| 2023-12-31 | AU$-3.79 Million ≈ $-2.68 Million |
-180.98% |
| 2022-12-31 | AU$4.68 Million ≈ $3.31 Million |
-64.84% |
| 2021-12-31 | AU$13.31 Million ≈ $9.41 Million |
+3.03% |
| 2020-12-31 | AU$12.91 Million ≈ $9.14 Million |
+334.30% |
| 2019-12-31 | AU$2.97 Million ≈ $2.10 Million |
-23.15% |
| 2018-12-31 | AU$3.87 Million ≈ $2.74 Million |
-44.35% |
| 2017-12-31 | AU$6.95 Million ≈ $4.92 Million |
-40.52% |
| 2016-12-31 | AU$11.69 Million ≈ $8.27 Million |
+231.88% |
| 2015-12-31 | AU$-8.86 Million ≈ $-6.27 Million |
-123.17% |
| 2014-12-31 | AU$-3.97 Million ≈ $-2.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Imagion Biosystems Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6727701400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$65.96 Million | % |
| Other Comprehensive Income | AU$3.20 Million | % |
| Other Components | AU$1.00 | % |
| Total Equity | AU$-2.16 Million | 100.00% |
Imagion Biosystems Ltd Competitors by Market Cap
The table below lists competitors of Imagion Biosystems Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Weststar Industrial Ltd
AU:WSI
|
$5.56 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$5.56 Million |
|
PURE ENERGY MINLS
F:AHG
|
$5.56 Million |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
$5.57 Million |
|
Brilliant Future AB
ST:BRILL
|
$5.55 Million |
|
GB Group plc
LSE:GBG
|
$5.55 Million |
|
Northern Shield Resources Inc.
V:NRN
|
$5.55 Million |
|
Azevedo & Travassos S.A
SA:AZEV3
|
$5.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imagion Biosystems Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,282,980 to -2,161,917, a change of 121,063.
- Net loss of 4,309,456 reduced equity.
- Share repurchases of 257,518 reduced equity.
- New share issuances of 3,500,263 increased equity.
- Other comprehensive income increased equity by 1,016,968.
- Other factors increased equity by 170,806.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.31 Million | -199.33% |
| Share Repurchases | AU$257.52K | -11.91% |
| Share Issuances | AU$3.50 Million | +161.91% |
| Other Comprehensive Income | AU$1.02 Million | +47.04% |
| Other Changes | AU$170.81K | +7.9% |
| Total Change | AU$- | % |
Book Value vs Market Value Analysis
This analysis compares Imagion Biosystems Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | AU$-193.74 | AU$0.02 | x |
| 2015-12-31 | AU$-432.37 | AU$0.02 | x |
| 2016-12-31 | AU$0.11 | AU$0.02 | x |
| 2017-12-31 | AU$0.04 | AU$0.02 | x |
| 2018-12-31 | AU$0.02 | AU$0.02 | x |
| 2019-12-31 | AU$0.33 | AU$0.02 | x |
| 2020-12-31 | AU$0.69 | AU$0.02 | x |
| 2021-12-31 | AU$0.51 | AU$0.02 | x |
| 2022-12-31 | AU$0.17 | AU$0.02 | x |
| 2023-12-31 | AU$-0.12 | AU$0.02 | x |
| 2024-12-31 | AU$-0.05 | AU$0.02 | x |
| 2025-12-31 | AU$-0.01 | AU$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imagion Biosystems Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13313.12%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-62.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -41159.99% | 0.02x | 0.00x | AU$-2.12 Million |
| 2015 | 0.00% | -80124.99% | 0.01x | 0.00x | AU$-3.51 Million |
| 2016 | -8.85% | -8620641.67% | 0.00x | 1.04x | AU$-2.20 Million |
| 2017 | -112.11% | -38775.26% | 0.00x | 1.10x | AU$-8.49 Million |
| 2018 | -215.75% | -4359.67% | 0.04x | 1.34x | AU$-8.73 Million |
| 2019 | -115.44% | -835.46% | 0.08x | 1.64x | AU$-3.73 Million |
| 2020 | -41.54% | -2607.47% | 0.01x | 1.09x | AU$-6.66 Million |
| 2021 | -45.28% | -2587.21% | 0.02x | 1.06x | AU$-7.36 Million |
| 2022 | -209.71% | -2071.95% | 0.05x | 2.13x | AU$-10.28 Million |
| 2023 | 0.00% | -1151.86% | 0.24x | 0.00x | AU$-12.10 Million |
| 2024 | 0.00% | -77.56% | 0.95x | 0.00x | AU$-1.84 Million |
| 2025 | 0.00% | -13313.12% | 0.02x | 0.00x | AU$-4.09 Million |
Industry Comparison
This section compares Imagion Biosystems Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $328,972,686
- Average return on equity (ROE) among peers: -22.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imagion Biosystems Ltd (IBX) | AU$-2.16 Million | 0.00% | N/A | $5.55 Million |
| Australian Clinical Labs Ltd (ACL) | $171.98 Million | 18.86% | 2.34x | $290.81 Million |
| Bcal Diagnostics Ltd (BDX) | $9.64 Million | -35.12% | 0.10x | $24.26 Million |
| Cryosite Ltd (CTE) | $3.89 Million | -31.47% | 0.12x | $36.61 Million |
| Genetic Signatures Ltd (GSS) | $49.34 Million | 3.56% | 0.10x | $10.77 Million |
| Genetic Technologies Ltd (GTG) | $11.16 Million | -105.27% | 0.33x | $4.01 Million |
| Healius Ltd (HLS) | $2.43 Billion | 1.58% | 0.49x | $200.38 Million |
| Integral Diagnostics Ltd (IDX) | $228.33 Million | 10.09% | 1.57x | $535.65 Million |
| Inoviq Ltd (IIQ) | $19.99 Million | -32.79% | 0.09x | $38.35 Million |
| Microba Life Sciences Ltd (MAP) | $38.72 Million | -32.74% | 0.21x | $15.94 Million |
About Imagion Biosystems Ltd
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more